Both cladribine and alemtuzumab may effect MS via B-cell depletion (2017)
Attributed to:
MidPlus: A Centre of Excellence for Computational Science, Engineering and Mathematics
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1212/nxi.0000000000000360
Publication URI: http://dx.doi.org/10.1212/nxi.0000000000000360
Type: Journal Article/Review
Parent Publication: Neurology Neuroimmunology & Neuroinflammation
Issue: 4